SynthesisScientific reports2025
Predicting the prognosis of breast cancer patients by using pan-immune-inflammation value: a systematic review and meta-analysis.
Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- First-Line Palbociclib/Letrozole Versus Ribociclib/Letrozole in Postmenopausal HR-Positive/HER2-Negative Metastatic Breast Cancer: A Retrospective Real-World Study and an Exploratory Composite Clinical-Inflammatory Risk Score.Medicina (Kaunas, Lithuania) · 2026Article
- A Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Proliferation-Inflammation (TIPI) Score.Journal of clinical medicine · 2026Article
- Prognostic significance of the pan-immune-inflammatory value (PIV) in gastric cancer: a retrospective cohort study.BMC cancer · 2026Article
- The pan-immune-inflammation value predicts stroke-associated pneumonia and poor outcome in spontaneous intracerebral hemorrhage: a machine learning approach.Frontiers in neurology · 2026Article
- Association of Preoperative Pan-Immune-Inflammation Value with Adverse Pathology and Oncological Outcomes Following Radical Prostatectomy: A Single-Center Retrospective Study.International journal of medical sciences · 2026Article
- Ki-67 and Platelet-to-Lymphocyte Ratio (PLR) as Predictors of Progression-Free Survival in Metastatic Breast Cancer Receiving CDK4/6 Inhibitors: Clinical Implications.Cancer management and research · 2026Article
- Clinical and pathological indicators for predicting disease-free survival after radical surgery in elderly patients with early-stage triple-negative invasive ductal carcinoma of the breast.Frontiers in oncology · 2026Article
- Study on risk stratification and treatment strategy of blood indicators in patients with moderate risk of GIST.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Available evidence has unequivocally established the significance of inflammation in the onset and advancement of cancer. Pan-immune-inflammation value (PIV) is an evaluation method that incorporates the role of different white blood cells (WBC) subsets to predict the progression of cancer. The main aim of this study is to assess the feasibility of the PIV score in predicting prognosis among women with breast cancer. A thorough search was performed on the Scopus, Europe PMC, Cochrane Library, and Medline databases up until September 25th, 2024, employing a combination of pertinent keywords. This investigation includes paper that explores the connection of PIV and survival in breast neoplasm. We utilized random-effects models to assess the hazard ratio (HR) and report the results together with their respective 95% confidence intervals (CI). Sixteen papers were chosen for analysis. The findings of our meta-analysis from multivariate data indicated that breast cancer patients who possessed high PIV score had a higher risk of shorter overall survival (OS) (HR 2.22; 95% CI 1.60-3.07, p < 0.00001, I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.